Figure 2 provides a comprehensive overview of Phase 3 clinical trials that evaluate various ICIs administered as first‐line treatments, either as monotherapies or in combination therapies, targeting patients with advanced NSCLC among different PD‐L1 expression levels. Here, CD274 is linked to non-small cell lung carcinoma.